Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
äŒæ¥ã³ãŒãFEMY
äŒç€ŸåFemasys Inc
äžå Žæ¥Jun 18, 2021
æé«çµå¶è²¬ä»»è
ãCEOãLee-Sepsick (Kathy)
åŸæ¥å¡æ°69
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jun 18
æ¬ç€Ÿæåšå°3950 Johns Creek Court
éœåžSUWANEE
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·30024
é»è©±çªå·17705003910
ãŠã§ããµã€ãhttps://www.femasys.com/
äŒæ¥ã³ãŒãFEMY
äžå Žæ¥Jun 18, 2021
æé«çµå¶è²¬ä»»è
ãCEOãLee-Sepsick (Kathy)